BACKGROUND
NSCLC, Lung cancer, death
LUNG CANCER, NSCLC
Lung cancer is the leading cause of cancer‐related death globally.The EGFR TKIs afatinib and osimertinib are recommended for the treatment of NSCLC harboring G719X, S768I, and L861Q mutations. These agents have demonstrated moderate anti‐tumor activity, with a median PFS of 8.2–10.7 months.Immune checkpoint inhibitors (ICIs) targeting the programmed death 1 (PD‐1)/PD ligand 1 (PD‐L1) pathway have revolutionized the treatment of advanced NSCLC; however, the observed OS benefit with second‐line ICI monotherapy over docetaxel in patients with NSCLC has failed to extend to Combining ICIs with antiangiogenic agents can result in synergistic antitumor effects.Sintilimab is a novel anti–PD‐1 monoclonal antibody (mAb) with encouraging antitumor activity in advanced NSCLC.